Pages that link to "Q27851560"
Jump to navigation
Jump to search
The following pages link to Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer (Q27851560):
Displaying 50 items.
- New drugs for medullary thyroid cancer: new promises? (Q26749308) (← links)
- Selective use of sorafenib in the treatment of thyroid cancer (Q26752891) (← links)
- Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib (Q26821959) (← links)
- Sorafenib in metastatic thyroid cancer: a systematic review (Q26828884) (← links)
- Cabozantinib for progressive metastatic medullary thyroid cancer: a review (Q26851709) (← links)
- Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer (Q27005701) (← links)
- Medical management of metastatic medullary thyroid cancer (Q27005897) (← links)
- CIViC database (Q27612411) (← links)
- RET M918T (Q27919563) (← links)
- Recent Updates on the Management of Medullary Thyroid Carcinoma (Q28066911) (← links)
- Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer (Q28072655) (← links)
- Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases (Q28391383) (← links)
- Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. (Q31170918) (← links)
- A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. (Q33569049) (← links)
- Update: the status of clinical trials with kinase inhibitors in thyroid cancer (Q33570056) (← links)
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update (Q33587821) (← links)
- Targeted therapy for cancer: the gastrointestinal stromal tumor model (Q33807742) (← links)
- Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib (Q33826258) (← links)
- New treatment modalities in advanced thyroid cancer (Q33864524) (← links)
- Cabozantinib in progressive medullary thyroid cancer (Q34185084) (← links)
- Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis (Q34272887) (← links)
- Update on thyroid cancer treatment (Q34310219) (← links)
- Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma (Q34468665) (← links)
- A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses (Q34538390) (← links)
- Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Q34758477) (← links)
- Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies (Q35038893) (← links)
- Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation (Q35068706) (← links)
- Targeted Treatment of Differentiated and Medullary Thyroid Cancer (Q35147151) (← links)
- Activated RET and ROS: two new driver mutations in lung adenocarcinoma (Q35206630) (← links)
- Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer (Q35295368) (← links)
- Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches (Q35370655) (← links)
- Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (Q35396089) (← links)
- Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI. (Q35703167) (← links)
- The landscape and therapeutic relevance of cancer-associated transcript fusions. (Q35744353) (← links)
- (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents (Q35744505) (← links)
- Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol co (Q35768717) (← links)
- Kinase inhibitors for advanced medullary thyroid carcinoma (Q35895485) (← links)
- Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis (Q36024704) (← links)
- Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer (Q36037051) (← links)
- Thyroid cancer: molecular aspects and new therapeutic strategies (Q36111541) (← links)
- SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. (Q36118305) (← links)
- Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer (Q36185863) (← links)
- The discovery and development of sorafenib for the treatment of thyroid cancer (Q36263304) (← links)
- Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review (Q36270115) (← links)
- Alopecia in patients treated with molecularly targeted anticancer therapies. (Q36316632) (← links)
- Thyroid cancer: pathogenesis and targeted therapy (Q36328045) (← links)
- New treatment in advanced thyroid cancer (Q36361115) (← links)
- The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. (Q36508942) (← links)
- Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers (Q36798134) (← links)
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer (Q36822111) (← links)